AMGN241018C365000
- 0.18
- 0.000.00%
Amgen Newsroom
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
Amgen Analyst Ratings
Amgen Inc. (NASDAQ:AMGN) Delivered A Better ROE Than Its Industry
Amgen Downgraded at Truist on MariTide Prospects for Obesity
Truist Financial Downgrades Amgen(AMGN.US) to Hold Rating, Announces Target Price $333
JPMorgan Chase, Goldman Sachs Share Gains Lead Dow's 430-Point Rally
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316
Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
High Dividend Growth + High Free Cash Flow Yield Stocks = a Winning Strategy
Amgen Inc. (NASDAQ:AMGN) Is Largely Controlled by Institutional Shareholders Who Own 78% of the Company
Goldman Sees a 'Relief Rally' Potential for These Option Calls Ahead of Earnings
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
Healthcare Stocks Are Showing Life Beyond Lilly and GLP-1s -- Barrons.com
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Unusual Options Activity: EXPE, ALAB and Others Attract Market Bets, EXPE V/OI Ratio Reaches 95.2
EST Oct 9th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Express News | Amgen Inc : JP Morgan Raises Target Price to $300 From $290
Zenas Started at Buy by Four Banks on Lead Drug Potential
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034